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ApoptosisAbstract New series of 1,2,4-triazolopyrimidine and 1,2,4-triazoloquinazoline derivatives were
designed, synthesized, and evaluated for their antitumor activity. Compounds 6, 11, 26, 29, 41,
44, 48, 49 and 58 were tested as antitumor agents by the use of DNA-binding assay on TLC-plates,
colorimetric assay for the degree of DNA-binding (Methyl green-DNA displacement assay), eval-
uation of antineoplastic activity against Ehrlich Ascites Carcinoma in mice, and ﬁnally modulation
of apoptosis. 5-Flurouracil, vitamin C and ethidium bromide were used as positive controls in these
techniques. Compound 26 proved to be the most active member of these series as antitumor agent
with IC50 value of 47 ± 1. Several characteristic features were observed to be essential for activity
such as the morpholine group and the phenylazo group, in addition the electron-withdrawing
groups favor the activity than the electron-donating ones.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
1,2,4-Triazolopyrimidine is one of the important ring systems
that has drawn the attention for its different biological activi-
ties. Literature survey has revealed the progressive ﬁndings
about its synthesis and antitumor activity (Hafez and El-Gaz-
zar, 2009; Huang et al., 2012; Takunaka et al., 2005; Zhang
et al., 2005). Furthermore, a series of pyrazolo[3,4-d]pyrimi-
dine derivatives was found to be potentially useful as cyclin-
dependant kinase inhibitors and showed antiproliferative
activity on cancer cell line (Maravcova et al., 2003). Moreover,
some functional groups such as substituted phenylazo and
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Chart 1 General structures of the proposed compounds.
S1346 G.S. Hassan et al.sulphonylphenyl moieties were reported to enhance the antitu-
mor activity (Saavedra et al., 2006). Furthermore, the signiﬁ-
cance of the a,b-unsaturated ketone moiety in the cytotoxic
activity of certain derivatives (Al-Omar et al., 2005) and their
incorporation in many fused ring systems has been reported, in
addition, these derivatives proved to be active as antitumor
agents (Al-Omary et al., 2012).
On the other hand, alkylating agents and intercalating
agents represent two major classes of antitumor drugs that
act by direct interaction with DNA. Based on this fact; meth-
ods for determination of the interaction of small molecular
weight compounds with DNA by DNA-binding assay (Pezz-
uto et al., 1991) and methyl green-DNA displacement assay
(Bronstein and Weber, 2001) have been applied. In addition,
apoptosis – a programmed form of cell death by which un-
wanted cells are removed from the body without causing
inﬂammation-has been tested as most anticancer drugs such
as topoisomerase inhibitors, alkylating agents, antimetabolites,
and hormone antagonists induce it in sensitive cells. The ten-
dency of a cancer cell to undergo apoptosis may be especially
important for the chemotherapy (Sﬁkakis et al., 1995).
Depending on these entire bases, it was found interesting to
synthesize a series of triazolopyrimidine bearing pyrazole ring,
phenylazo and sulphonylphenyl moieties to afford compounds
of types (A–C), in addition to design and synthesis of new con-
densed triazolopyrimidine and triazoloquinazoline analogs of
general formula (D) and (E). The newly synthesized com-
pounds were evaluated for their antitumor activity throughscreening their ability to interact with DNA which is known
as the major mechanism of action of several known antitumor
agents.2. Materials and methods
Melting points were recorded using Fisher-Johns melting point
apparatus and are uncorrected. Microanalysis was performed
in the microanalytical unit, Cairo University. IR was recorded
on Mattson 5000 FT-IR spectrophotometer. 1H NMR spectra
were performed in (DMSO-d6) and were obtained on FT-
NMR (200 MHz) Gemini Varian spectrometer using TMS as
internal standard (chemical shift in ppm, d units) in the micro-
analytical unit, Cairo University. MS analyses were performed
on JEOL JMS-600H spectrometer in the microanalytical unit,
Cairo University. TLC plates (RP-18 F254; 0.25 mm) were pur-
chased from Merck, Germany. DNA, Ethidium bromide,
Anisaldehyde, DNA–Methyl green complex, 5-Fluorouracil
and ascorbic acid (vitamin C) were purchased from Sigma–Al-
drich Co., USA. Methanol, dimethyl sulfoxide (DMSO) and
all other chemicals are of high analytical grade, and are ob-
tained from El Nasr Co. for Pharmaceutical Chemicals, Egypt.
The cells of Ehrlich ascites tumor were obtained from the Na-
tional Cancer Institute, Cairo, Egypt. Adult Swiss male albino
mice (20–25 gm) of both sexes were used in this experiment.
Animals were housed in microlon boxes in a controlled envi-
ronment (temperature 25 ± 2 C and 12 h dark/light cycle)
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3, 20–23, 36–40, 46, 47, 53 were previously prepared (Williams,
1962; Vejdelek et al., 1976; Al-Khamees et al., 1993; El-Sub-
bagh et al., 2000; Dimmock et al., 2003). Yield percentage,
melting points and the elemental analysis for all the newly syn-
thesized compounds are recorded in Table 1.
2.1. Chemistry
2.1.1. Ethyl 7-chloro-2-morpholino-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxylate (4)
A mixture of compound 3 (Al-Khamees et al., 1993) (0.29 g,
0.001 mol) and POCl3 (10 ml) was heated under reﬂux for
6 h. After cooling, the resultant solution was poured into
ice water, and neutralized with ammonia solution. The
formed precipitate was ﬁltered, washed with water, dried
and crystallized from aqueous ethanol to yield 0.11 g (35
%) of 4, m.p. 195–8 C. IR, 1755(CO). 1H NMR: d 1.25
(t, 3H, CH2CH3), 2.86–2.91 (m, 4H, morpholine-H), 3.62–
3.64 (m, 4H, morpholine-H), 4.31 (q, 2H, CH2CH3), 8.45
(s, 1H, pyrimidine-H). MS m/z (%); 311 (53.7, M+), 313
(20.4, M+2).
2.1.2. 7-Morpholino-5H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-
a]pyrimidin-3(2H)-one (5)
2.1.2.1. Method A. Hydrazine hydrate 98% (2.5 g, 0.05 mol)
was added dropwise to a stirred solution of compound 3 (Al-
Khamees et al., 1993) (2.93 g, 0.01 mol) in absolute ethanol
(15 ml) over a period of 15 min. The reaction mixture was
heated under reﬂux for 14 h. Excess solvent was evaporated
under vacuum; the formed precipitate was separated, washed
with ethanol and used for the preparation of compounds 10
and 11 without further puriﬁcation.
2.1.2.2. Method B. Hydrazine hydrate 98% (2.5 g, 0.05 mol)
was added dropwise to a stirred solution of compound 4
(3.11 g, 0.01 mol) in absolute ethanol (15 ml) over a period
of 15 min. The reaction mixture was heated under reﬂux for
10 h. Excess solvent was evaporated under vacuum; the formed
precipitate was separated, washed with ethanol and used for
the preparation of same compounds. 5 1H NMR; d 2.54–
2.58 (m, 4H, morpholine-H), 3.68–3.84 (m, 4H, morpholine-
H), 7.55 (brs, 1H, NH-pyrimidine, D2O-exchang), 8.48 (brs,
1H, NH-pyrazole, D2O-exchang.), 10.03 (s, 1H, pyrimidine-
H). MS m/z (%); 261 (1.25, M+), 43 (100).
2.1.3. 7-Morpholino-2-substituted phenyl-5H-pyrazolo[4,3-
e][1,2,4]triazolo[1,5-a]pyrimidin-3(2H)-ones (6–9)
Compound 3 (2.93 g, 0.01 mol) was added portionwise to a
stirred solution of the appropriate phenyl hydrazine
(0.015 mol) in ethanol (50 ml). The reaction mixture was
heated under reﬂux for 16-18 h. On cooling, the separated solid
was ﬁltered, washed with ice water, dried and crystallized from
ethanol. Yield percentage and melting points are recorded in
Table 1. 6 1H NMR: d 2.61–2.63 (m, 4H, morpholine-H),
3.75–3.89 (m, 4H, morpholine-H), 6.68–7.12 (m, 5H, Ar–H),
7.61 (brs, 1H, NH-pyrimidine, D2O-exchang), 9.58 (s, 1H,
pyrimidine-H). MS m/z (%); 337 (0.54, M+), 128 (100). 7 1H
NMR: d 2.51–2.54 (m, 4H, morpholine-H), 3.78–3.85 (m,4H, morpholine-H), 6.53–6.92 (m, 4H, Ar-H), 7.65 (brs, 1H,
NH-pyrimidine, D2O-exchang.), 9.43 (s, 1H, pyrimidine-H).
MS m/z (%); 371 (0.54, M+), 373 (0.21, M+2). 8 1H NMR:
d 2.49–2.53 (m, 4H, morpholine-H), 3.66–3.76 (m, 4H, mor-
pholine-H), 4.15 (s, 3H, OCH3), 5.44 (brs, 1H, NH-pyrimidine,
D2O-exchang.), 6.83–6.91 (m, 4H, Ar–H), 8.45 (s, 1H, pyrim-
idine-H). MS m/z (%); 367 (3.41, M+). 9 1H NMR: d 2.64–
2.69 (m, 4H, morpholine-H), 3.75–3.83 (m, 4H, morpholine-
H), 6.37–6.68 (m, 3H, Ar–H), 7.42 (brs, 1H, NH-pyrimidine,
D2O-exchang.), 8.96 (s, 1H, pyrimidine-H). MS m/z (%); 427
(3.41, M+).
2.1.4. 7-Morpholino-2-((4-substituted) phenyl)sulphonyl-5H-
pyrazolo[4,3-e][1,2,4]triazolo [1,5-a]pyrimidin-3(2H)-ones
(10, 11)
A mixture of compound 5 (0.261 g, 0.001 mol) and the appro-
priate benzenesulphonyl chloride (0.0015 mol) was reﬂuxed in
pyridine (10 ml) for 6 h. After cooling, the produced solution
was poured into ice water. The separated solid was ﬁltered,
washed with water and dried. Yield percentage and melting
points are recorded in Table 1. 10 1H NMR: d 2.76–2.92 (m,
4H, morpholine-H), 3.39–3.63 (m, 4H, morpholine-H), 7.85–
8.21 (m, 6H, Ar–H, NH-pyrimidine, D2O-exchang.), 8.51 (s,
1H, pyrimidine-H). MS m/z (%); 401 (1.63, M+), 114 (100).
11 1H NMR; d 2.19 (s, 3H, CH3), 2.84–2.96 (m, 4H, morpho-
line-H), 3.35–3.69 (m, 4H, morpholine-H), 8.21 (m, 5H, Ar–H,
NH-pyrimidine, D2O-exchang.), 8.64 (s, 1H, pyrimidine-H).
MS m/z (%); 415 (2.48, M+).
2.1.5. 5-Methyl-2-morpholino (or 4-methylpiperazino)-6-(4-
substituted phenylazo)-4H,7H-[1,2,4]triazolo [1,5-
a]pyrimidin-7-ones (25–29)
A mixture of the appropriate ethyl 2-(4-substituted phenylhyd-
razono)-3-oxobutanoates (20–23) (Williams, 1962,Vejdelek
et al., 1976) (0.001 mol) and 5-amino-3-substituted-1H-1;2,4-
triazoles (1, 24) (0.001 mol) was reﬂuxed in glacial acetic acid
(10 ml) for 5 h. After cooling, the reaction mixture was concen-
trated under vacuum. The obtained solid was ﬁltered, dried
and crystallized from petroleum ether. Yield percentage and
melting points are recorded in Table 1. 25: 1H NMR; d 2.04
(s, 3H, CH3), 2.64–2.68 (m, 4H, morpholine-H), 3.56–3.63
(m, 4H, morpholine-H), 7.83–8.20 (m, 4H, Ar–H), 8.24 (brs,
1H, NH-pyrimidine, D2O-exchang.). MS m/z (%); 373 (2.26,
M+), 374 (0.23, M+1), 108 (100). 26: 1H NMR; d 2.30 (s,
3H, CH3), 2.54–2.59 (m, 4H, morpholine-H), 3.45–3.49 (m,
4H-morpholine-H), 7.57–8.26 (m, 4H, Ar–H), 8.36 (brs, 1H,
NH-pyrimidine, D2O-exchang.). MS m/z (%); 384 (31.84,
M+), 279 (100). 27: 1H NMR; d 2.22 (s, 3H, CH3), 2.53–
2.55 (m, 4H, morpholine-H), 3.73–3.82 (m, 4H, morpholine-
H), 3.93 (s, 3H, OCH3), 7.07–7.73 (m, 4H, Ar–H), 8.32 (brs,
1H, NH-pyrimidine, D2O-exchang.). MS m/z (%); 369 (18.3,
M+). 28: 1H NMR; d 2.20 (s, 3H, CH3), 2.35 (s, 3H, N–
CH3), 2.56–2.79 (m, 8H, piperazine-H), 7.38–7.51 (m, 4H,
Ar–H), 8.29 (brs, 1H, NH-pyrimidine, D2O-exchang.). MS
m/z (%); 431 (21.5, M+), 433 (0.34, M+2), 125 (100). 29: 1H
NMR; d 2.21 (s, 3H, CH3), 2.32 (s, 3H, CH3), 2.56–2.69 (m,
8H, piperazine-H), 4.01 (s, 3H, OCH3), 7.51–8.05 (m, 4H,
Ar–H), 8.33 (brs, 1H, NH-pyrimidine, D2O-exchang.). MS
m/z (%); 382 (8.3, M+).
Table 1 Physical properties, yields, molecular formulae and elemental analysis of compounds (5–59).
No. X Y Z R R1 R2 R3 Yield % m.p. (C) Molecular
Formulaea
Analysis
Calc. Found
5 O – – H – – – 44 Decomp.at 202 C10H11N7O2 C 45.98 46.02
H 4.24 4.51
N 37.53 37.84
6 O – – C6H5 – – – 58 208–10 C16H15N7O2 C 56.97 57.11
H 4.48 4.65
N 29.07 29.25
7 O – – 4-Cl–C6H4 – – – 38 235–7 C16H14ClN7O2 C 51.69 51.93
H 3.80 4.11
N 26.37 26.72
8 O – – 4-CH3OC6H4 – – – 49 175–9 C17H17N7O3 C 55.58 55.82
H 4.66 4.99
N 26.69 26.82
9 O – – 2,4-(NO2)2C6H3 – – – 36 246–9 C16H13N9O6 C 44.97 45.21
H 3.07 3.24
N 29.50 29.85
10 O – – – H – – 64 >300 C16H15N7O4S C 47.88 48.01
H 3.77 3.93
N 24.43 24.74
11 O – – – CH3 – – 55 275–8 C17H17N7O4S C 49.15 49.38
H 4.12 4.42
N 23.60 23.89
25 O – – – – Cl – 58 278–80 C16H16ClN7O2 C 51.41 51.58
H 4.31 4.72
N 26.23 26.30
26 O – – – – NO2 – 78 108–9 C16H16 N8O4 C 50.00 50.37
H 4.20 4.59
N 29.15 29.42
27 O – – – – OCH3 – 53 209–11 C17H19 N7O3 C 55.28 55.53
H 5.18 5.31
N 26.54 26.73
28 NCH3 – – – – Br – 66 249–50 C17H19BrN8O C 47.34 47.63
H 4.44 4.60
N 25.98 26.13
29 NCH3 – – – – OCH3 – 48 Decomp. at 195 C18H22 N8O2 C 56.53 56.80
H 5.80 6.01
N 29.30 29.69
41 O CH2 – – – – H 56 265–7 C26H25N5O C 73.74 74.00
H 5.95 6.11
N 16.54 16.87
41 O CH2 – – – – Br 78 Decomp.at 240 C26H23Br2N5O C 53.72 53.99
H 3.99 4.00
N 12.05 12.39
43 N–CH3 CH2 – – – – Cl 59 230–2 C27H26Cl2N6 C 64.16 64.32
H 5.18 5.28
N 16.63 16.84
44 O N–CH3 – – – – OCH3 52 230–1 C28H30N6O3 C 67.45 67.61
H 6.06 6.29
N 16.86 17.11
45 N–CH3 N–CH3 – – – – H 40 210–1 C27H29N7 C 71.81 72.09
H 6.47 6.77
N 21.71 21.94
48 O CH2 – – – – Cl 56 251–3 C19H20ClN5O C 61.70 61.91
H 5.45 5.75
N 18.94 19.14
49 O CH2 – – – – OCH3 48 199–201 C20H23 N5O2 C 65.73 65.99
H 6.34 6.54
N 19.16 19.37
54 – – N–CH3 – – – – 91 136–9 C13H18N2O3S C 55.30 55.64
H 6.43 6.49
N 9.92 10.05
56 – – O – – – – 78 150–3 C15H20N2O4S C 55.54 55.72
H 6.21 6.38
N 8.64 8.84
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Table 1 (continued)
No. X Y Z R R1 R2 R3 Yield % m.p. (C) Molecular
Formulaea
Analysis
Calc. Found
57 N–CH3 – 71 170–2 C15H20N2O4S C 56.95 57.03
H 6.87 6.95
N 12.45 12.70
58 O – O – – – – 80 221–3 C19H22N6O4S C 53.01 53.24
H 5.15 5.40
N 19.52 19.75
59 O – NCH3 – – – – 62 187–9 C20H25N7O3S C 54.16 54.46
H 5.68 5.86
N 22.11 22.46
a Analyzed for C,H,N; results were within ±0.4 % of the theoretical values for the formulae given.
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benzylidene)-9-(4-substituted phenyl)-5,6,7,8-
tetrahydro[1,2,4]triazolo[5,1-b]quinazolines (41–43), and 7-
methyl-2-morpholino (or 4-methylpiperazino)-5-(4-substituted
benzylidene)-9-(4-substituted phenyl)-5,6,7,8-tetrahydro-
pyrido[4,3-d][1,2,4]triazolo[1,5-a]pyrimidines (44, 45)
Sodium metal (0.5 g, 0.02 mol) was added portionwise to abso-
lute ethanol (20 ml) over a period of 15 min. To the resulted
solution, the appropriate ketone (El-Subbagh et al., 2000;
Dimmock et al., 2003) (36–40) (0.01 mol) and the appropriate
triazole derivative (1, 24) (0.01 mol) were added. The resulting
mixture was heated at reﬂux for 15 h. The solvent was evapo-
rated under reduced pressure; the solid formed was separated
and crystallized from ethanol to yield compounds (41–45).
Yield percentage and melting points are recorded in Table 1.
41: 1H NMR; d 2.38–2.50 (m, 6H, C6–H, C7–H, C8–H),
2.55–2.57 (m, 4H, morpholine-H), 3.68–3.71(m, 4H, morpho-
line-H), 7.45–7.88 (m, 11H, Ar–H and CH‚C). MS m/z
(%); 423 (100, M+). 42: 1H NMR; d 1.68–2.40 (m, 6H, C6–
H, C7–H, C8–H), 2.57–2.61 (m, 4H, morpholine-H), 3.54–
3.62 (m, 4H, morpholine-H), 7.47–7.76 (m, 8H, Ar-H), 8.02
(s, 1H, CH‚C). MS m/z (%); 581 (100, M+), 583 (28.75,
M+2). 43: 1H NMR; d 2.21 (s, 3H, N–CH3), 2.45–2.46 (m,
6H, C6–H, C7–H, C8–H), 2.54–3.26 (m, 8H, piperazine-H),
7.46–7.64 (m, 8H, Ar–H), 8.04 (s, 1H, CH‚C). MS m/z
(%); 504 (22.8, M+). 44: 1H NMR; d 2.29 (s, 3H, N–CH3),
2.51–3.31 (m, 8H, morpholine-H, C6–H, C8–H), 3.62–3.65
(m, 4H, morpholine-H), 3.95 (s, 6H, OCH3), 7.02–7.63 (m,
8H, Ar–H), 8.05 (s, 1H, CH‚C). MS m/z (%); 498 (100,
M+). 45: 1H NMR; d 2.23 (s, 3H, N–CH3), 2.50 (s, 3H, N–
CH3), 2.49–3.30 (m, 12H, C6–H, C8–H, piperazine-H), 7.22–
7.84 (m, 10H, Ar–H), 8.53 (s, 1H, CH‚C). MS m/z (%);
451 (100, M+).
2.1.7. 2-Morpholino-9-(4-substituted phenyl)-5,6,7,8-
tetrahydro-[1,2,4]triazolo[5,1-b] quinazolines (48, 49)
Sodium metal (0.5 g, 0.02 mol) was added portionwise to abso-
lute ethanol (20 ml) over a period of 15 min. To the resulting
solution, the appropriate ketone (Dimmock et al., 2003) (46,
47) (0.01 mol) and 5-amino-3-morpholino-1H-1,2,4-triazole
(1) (1.69 g, 0.01 mol) were added. The resulting solution was
heated under reﬂux for 17 h. The solvent was then evaporated
under vacuum; the solid formed was ﬁltered and crystallized
from ethanol to yield compounds (48, 49).Yield percentage
and melting points are recorded in Table 1. 48: 1H NMR; d1.58–2.35 (m, 8H, C5–H, C6–H, C7–H, C8–H), 2.85–2.93 (m,
4H, morpholine-H), 3.53–3.60 (m, 4H, morpholine-H), 7.20–
7.53 (m, 4H, Ar–H).MSm/z (%); 369 (100, M+), 370 (11.39,
M+1). 49: 1H NMR; d 1.54–2.21 (m, 8H, C5–H, C6–H, C7–
H, C8–H), 2.79–2.82 (m, 4H, morpholine-H), 3.59–3.68 (m,
4H, morpholine-H), 3.93 (s, 3H, OCH3) 6.88–7.43 (m, 4H,
Ar–H). MS m/z (%); 365 (100, M+).
2.1.8. 1-(4-(4-methylpiperazin-1-ylsulfonyl)phenyl)ethanone
(54)
A mixture of 4-acetylbenzene sulphonylchloride (50, 2.18 g,
0.01 mol), 1-methyl piperazine (52, 2.53 g, 0.01 mol) and cata-
lytic amount of triethylamine (three drops) in toluene (10 ml)
was heated to reﬂux for 7 h. The solvent was evaporated under
vacuum and the remaining solid was crystallized from ethanol
to yield the desired compounds. Yield percentage and melting
points are recorded in Table 1. 54: 1H NMR; d 2.21 (s, 3H, N–
CH3), 2.44 (s, 3H, CH3), 2.49–2.75 (m, 4H, piperazine-H),
3.25–3.55 (m, 4H, piperazine-H), 7.85–8.22 (m, 4H, Ar–H).
MS m/z (%); 282 (3.15, M+)
2.1.9. 3-Dimethylamino-1-(4-(substituted
sulphonyl)phenyl)prop-2-en-1-ones (56, 57)
A mixture of the appropriate acetophenones (53, 54)
(0.01 mol) and DMF-DMA (55) (10 ml) was heated under re-
ﬂux for 7 h. After cooling, the reaction mixture was evaporated
under vacuum; the produced solid was separated and crystal-
lized from ethanol to yield the desired compounds. Yield per-
centage and melting points are recorded in Table 1. 56: 1H
NMR; d 2.55–2.83 (m, 4H, morpholine-H), 3.35 (s, 6H,
CH3), 3.63–3.71 (m, 4H, morpholine-H), 5.94 (d, 2H,
CH‚CH), 7.76–8.13 (m, 4H, Ar–H). MS m/z (%); 324
(34.18, M+). 57: 1H NMR; d 2.24 (s, 3H, N-CH3), 2.61–2.75
(m, 4H, piperazine-H), 3.01 (s, 6H, CH3), 3.68–3.87 (m, 4H,
piperazine-H), 5.37 (d, 2H, CH‚CH), 7.41–8.08 (m, 4H,
Ar–H). MS m/z (%); 337 (100, M+).
2.1.10. 2-Morpholino-5-(4-(substituted sulphonyl)phenyl)-
[1,2,4]triazolo[1,5-a] pyrimidines (58, 59)
A mixture of the appropriate compound (56, 57) (0.01 mol), 5-
amino-3-morpholino-1H-1,2,4-triazole (1) (1.69 gm, 0.01 mol)
and sodium acetate (0.5 gm) in glacial acetic acid (10 ml) was
heated under reﬂux for 10 h. The solvent was then concen-
trated under reduced pressure and the solid formed was ﬁl-
tered, washed with water and crystallized from ethanol to
Table 3 Grouping of animals in Ehrlich Ascites Carcinoma
test.
Group No. Treatment (I.P.) No. of mice
1 Normal (untreated) 10
2 Control (Ehrlich only) 10
3 26 (20 mg/kg) 10
4 5-FU (20 mg/kg) 10
S1350 G.S. Hassan et al.yield the desired products. Yield percentage and melting points
are recorded in Table 1. 58: 1H NMR; d 2.55–2.83 (m, 8H,
morpholine-H), 3.63–3.71 (m, 8H, morpholine-H), 7.47 (d,
1H, C6–H), 7.95–8.52 (m, 4H, Ar–H), 8.69 (d, 1H, C7–H).
MS m/z (%); 430 (51.0, M+). 59: 1H NMR; d 2.21 (s, 3H,
N–CH3), 2.55–2.83 (m, 8H, morpholine-H, piperazine-H),
3.39–3.66 (m, 8H, morpholine-H, piperazine-H), 7.43 (d, 1H,
C6–H), 7.95–8.52 (m, 4H, Ar–H), 8.64 (d, 1H, C7–H). MS
m/z (%); 443 (1.3, M+).
2.2. DNA-binding assay on TLC-plates
The TLC plates used in the assay were pre-developed using
methanol:water (8:2). Compounds 6, 11, 26, 29, 41, 44, 48,
49 and 58 were then applied (5 mg/ml in methanol) at the ori-
gin, followed by spotting of DNA (1 mg/ml in methanol/water
mixture (8:2)) at the same positions at the origin. Ethidium
bromide was used as a positive control. After complete spot-
ting, the plates were developed with the same solvent system,
and the positions of DNA were visualized by spraying the
plates with anisaldehyde, which produces a blue color with
DNA. The intensity of the color was proportional to the quan-
tity of DNA added to the plate (Pezzuto et al., 1991).
2.3. Colorimetric assay for the degree of DNA-binding (Methyl
green-DNA displacement assay)
DNA–methyl green complex (20 mg) was suspended in 100 ml
of 0.05 M Tris–HCl buffer (pH 7.5) containing 7.5 mmole
MgSO4 and stirred at 37 C. The calculated amounts of sam-
ples were placed in Eppendorff tubes, and 200 ll of the
DNA/methyl green solution was added to each tube. The sam-
ples were incubated in the dark at ambient temperature for
24 h, and the ﬁnal absorbance of each sample was determined
at 630 nm. The results were recorded in the form of the IC50 of
each compound, which is the sample concentration required to
produce 50% decrease in the initial absorbance of the DNA–
methyl green complex. (Table 2) (Bronstein and Weber, 2001).
2.4. Evaluation of antineoplastic activity against Ehrlich Ascite
Carcinoma in mice
The animals were classiﬁed into four groups as shown in
Table 3. Animals in the treated groups (from 2 to 4) were inoc-
ulated with 2 · 106 Ehrlich ascites cells/mouse on the day zero.
Treatment was started 24 h after inoculation by intra-protenialTable 2 The IC50 values of compounds 6, 11,
26, 29, 41, 44, 48, 49, 57.
Compound No. DNA/methylgreenic50, MG/ML
26 47 ± 1
29 59 ± 2
44 63 ± 2
41 63 ± 2
6 66 ± 2
58 67 ± 1
11 69 ± 2
49 71 ± 2
48 73 ± 2
Ethidium Br 1.7 ± 2(I.P.) injection of the drug. The animals in the group (3) were
injected by compound 26 in a dose of 20 mg/kg of body
weight, the standard group (group 4) has also received I.P.
treatment with 20 mg/kg of body weight of 5-ﬂuorouracil (5-
FU). The control group (2) was treated with the same volume
of 0.9% sodium chloride solution. All the treatments were gi-
ven for nine successive days (Table 3) (Hazra et al., 2002).
2.5. Modulation of apoptosis
Neutrophils (>98% pure on May-Giemsa stain) were isolated
from peripheral blood of normal healthy volunteer donors and
from osteoarthritic and rheumatoid arthritic patients by a
combination of dextran sedimentation and centrifugation
through discontinuous plasma percol gradients. These neutro-
phils were then re-suspended with 10% autologous platelet
rich plasma derived serum (PRPDS) and 100 lg/l of penicillin
and streptomycin and divided into ﬁve equal volumes in sepa-
rate culture tubes. Cells were incubated (at 37 C in a 5% car-
bon dioxide) as follows: (1) Only cells, (2) Cells + DMSO at
0.01% v/v., (3) Cells + each compound in DMSO at a dose
of 50 mmole/ml culture. (The age of neutrophils in culture
was calculated while starting the culture at time zero (or base
line), 24, 48 and 72 h). At the determined times, cells were re-
moved from culture and counted on a hemocytometer. Cell
viability was determined by trypan blue dye exclusion test;
one volume of trypan blue (0.4% GiBCo) was added to ﬁve
volumes of cells at room temperature for 5 min. The neutro-
phil apoptosis in each culture was assessed: (i) Morphology
(Giemsa and Acridine orange stains), (ii) DNA Fragmenta-
tion. For assessment of the percentage of cells showing mor-
phology of apoptosis 500 cells/slide were examined for each
case at different times (0, 24, 48, and 72 h) in the presence or
absence of the drugs used. Neutrophils were considered apop-
totic if they exhibited the highly characteristic morphological
features of chromatin aggregation, nuclear pyknosis and cyto-
plasmic vaculation. The apoptotic neutrophil percentage at
different times was calculated after addition of tested com-
pounds and the results were then compared statistically using
the F-test and student’s t-test (Kumagai et al., 1995). Secondly,
assessment of chromatin fragmentation in neutrophils was
done by the modiﬁcation of methods previously used for thy-
mocytes (Lahti et al., 1995).
3. Results and discussion
3.1. Chemistry
The strategy for the synthesis of the target compounds is illus-
trated in schemes 1-5. 5-Amino-3-morpholino-1H-1,2,4-triazole
Synthesis and antitumor testing of certain new fused triazolopyrimidine and triazoloquinazoline derivatives S1351(1) was allowed to react with diethyl ethoxymethylenemalonate
(2) in glacial acetic acid to afford the target compound ethyl 2-
morpholino-7-oxo-4H,7H-[1,2,4]triazolo[1,5-a]pyrimidine-6-
carboxylate (3) in 79% yield. The hydroxyl group of compound
(3) was replaced with chlorine by reﬂuxing in phosphorus
oxychloride to produce ethyl 7-chloro-2-morpholino-
[1,2,4]triazolo[1,5-a] pyrimidine-6-carboxylate (4). 7-morpho-
lino-2-(un)substituted-5H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-a]
pyrimidin-3(2H)-ones (5–9) were prepared via either the reac-
tion of compound 3 with either hydrazine hydrate or (substi-
tuted) phenyl hydrazine in ethanol, or by the reaction of
compound 4 with the same reagents in ethanol. 7-Morpholino-
5H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-a] pyrimidin-3(2H)-one (5)
was allowed to react with the appropriate benzenesulphonyl
chloride in pyridine to obtain 7-morpholino-2-(substituted
phenyl)sulphonyl-5H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-a]pyr-
imidin-3(2H)-ones (10, 11) in yields of 64 and 55%, respectively
(Scheme 1). (see Chart 1)
5-Methyl-2-substituted-6-(4-substituted phenylazo)-4H,7H-
[1,2,4]triazolo[1,5-a]pyrimidin-7-ones (25–29) were prepared
by the condensation of the substituted aminotriazoles (1, 24)NH
N
O
NH2N
N
+
N
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N
N
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COOEt
N
NO N
N
N
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COOEt
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N
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N
N
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Scheme 1 Synthesis of thewith ethyl 2-(4-substituted phenylhydrazono)-3-oxobutanoates
(20–23) in glacial acetic acid to give the required compounds in
48–78% yields (Scheme 2).
Compounds 41–45 were prepared via the condensation
of either 2,6-bis(4-substituted benzylidene)cyclohexanones
(36–38) or 3,5-bis(4-substituted benzylidene)-1-methylpiperi-
din-4-ones (39, 40) with aminotriazoles (1, 24) in freshly
prepared sodium ethoxide (Scheme 3).
For the preparation of 2-(substituted benzylidene)cyclo-
hexanones, different molar ratios of the starting materials were
used. 2-(4-Substituted benzylidene)cyclohexanones (46, 47)
were obtained through reacting cyclohexanone (30) and the
appropriate aldehyde (33, 35) in a molar ratio of 7:1 for
24 h. Compounds 48 and 49 were prepared by following the
same procedure for the preparation of compounds 41–45
(Scheme 4).
4-(Substituted sulphonyl)acetophenones (53, 54) were pre-
pared according to the procedure mentioned by Press et al.,
1981. A mixture of 4-acetyl benzenesulphonylchloride (50)
was reﬂuxed with either morpholine (51) or N-methylpipera-
zine (52) in toluene in the presence of the catalytic amount( EtO ) CH = C
COOEt
COOEt Glacial
acetic
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N
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Scheme 2 Synthesis of the target compounds 25–29.
S1352 G.S. Hassan et al.of triethylamine to obtain the target compounds in yield of 88
and 91% respectively (Vejdelek et al., 1976). Reﬂuxing 4-
(substituted sulphonyl)acetophenones (53 and 54) in
an excess of DMFDMA (55) yielded compounds 56 and 57
in yield 78 and 71% respectively. The condensation between
5-amino-3-morpholino-1H-1,2,4-triazole (1) and 3-dimethyl-
amino-1-(4-(substituted sulphonyl)phenyl)prop-2-en-1-ones
(56 and 57) in reﬂuxing glacial acetic acid in the presence of so-
dium acetate yielded the desired compounds 58 and 59
(Scheme 5).
3.2. Biological screening
Twenty compounds of the newly synthesized ones have been
subjected to DNA-binding assay and methyl green-DNA dis-
placement assay in order to study the differences in biological
response that might result upon incorporating the triazole moi-
ety into different cyclic structures.
3.2.1. DNA-binding assay on TLC-plates
This technique depends on comparing the difference in DNA
retaining to the origin between DNA complex with the tested
compounds and that with ethidium bromide, a compound
known to be good intercalator with DNA. This migration
was observed when methanol: water (8:2) was used as an elu-
tion solvent. Among all the tested compounds; compound 26
showed the best afﬁnity to DNA between the tested com-pounds which was demonstrated by retaining the complex at
the origin or by its migration for a very short distance. Com-
pounds 6, 11, 29, 41, 44 and 58 showed moderate afﬁnity.
The rest of the tested compounds showed the lowest afﬁnity to-
ward DNA.
3.2.2. Colorimetric assay for the degree of DNA-binding
(Methyl green-DNA displacement assay)
This colorimetric assay was used to measure the degree of dis-
placement of methyl green from DNA by the tested com-
pounds. The degree of displacement was determined
spectrophotometrically by a decrease in DNA–methyl green
absorbance. The results were highly consistent with those ob-
tained from the DNA-binding assay on TLC-plates. Table 2
showed the most active screened compounds arranged in an
increasing order for their IC50 values (calculated as lg/ml).
The obtained data revealed that compound 26 is the most ac-
tive member with IC50 value (the concentration required to
produce 50% decrease in the initial absorbance of the DNA–
methyl green complex) equals 47. The recorded values repre-
sent the mean ± SD, where n= 3–5 separate determinations.
3.2.3. Evaluation of antineoplastic activity against Ehrlich
Ascite Carcinoma in mice
The prolongations of the life span of Ehrlich Ascite Carcinoma
(EAC) bearing hosts and the recovery of normal biochemical
and hematological proﬁles are two important measures that
YO
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Scheme 3 Synthesis of the target compounds 41–45.
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Table 4 The % increase in lifespan for treated group over the
control group.
Group No. Treatment (I.P.) % increase in lifespan
1 Normal (untreated) 71.43
2 Control (Ehrlich only) Zero
3 26 41
4 5-FU 42.86
S1354 G.S. Hassan et al.have been used in this in vivo testing for the evaluation of the
antineoplastic activity for compound 26, the most active com-
pound among the newly synthesized derivatives, selected on
the basis of the results obtained from the previous evaluation
methods, where it showed the highest DNA-afﬁnity. The ﬁrstTable 5 Modulation of apoptosis results.
Comp. No. % Apoptic Neutrophil (Mean ± SD)
0 h 24 h
58 0.86 ± 0.01 25 ± 0.
59 0.79 ± 0.02 20 ± 0.
44 0.66 ± 0.01 16 ± 0.
41 0.57 ± 0.03 13 ± 0.
26 0.28 ± 0.06 8 ± 0.
Untreated 0.28 ± 0.4 4.4 ± 0.
Vit. C 0.42 ± 0.01 18 ± 0.measure that can be used to compare between the
antineoplastic activities for the tested compounds is the in-
crease in survival time for each treated group over the control
group (Gupta et al., 2000). The mean survival time (MST) for
each group was calculated by dividing the total survival times
for all the mice in that group by the number of mice in the
same group, then the percent increase in lifespan for each
group over the control group was calculated as follows:
%increase in lifespan over control
¼ MST of treated group
MST of control group
 100 100
By comparing the % increase in lifespan over the control
group in each treated group, it was found that compound 26
has shown almost the same increase in life span that produced
the standard drug 5-FU (Table 4).48 h 72 h
02 33 ± 0.02 53 ± 0.05
04 33 ± 0.04 52 ± 0.01
04 30 ± 0.05 39.1 ± 0.04
03 29.22 ± 0.02 29.5 ± 0.04
05 27.5 ± 0.05 18.2 ± 0.04
04 14.40 ± 0.03 13.3 ± 0.03
02 33.2 ± 0.04 58 ± 0.02
Synthesis and antitumor testing of certain new fused triazolopyrimidine and triazoloquinazoline derivatives S13553.2.4. Modulation of apoptosis
The present study was designed to investigate the possible
involvement of apoptosis of blood neutrophils by the tested
compounds. Blood neutrophils were prepared, cultured, and
incubated for 24, 48 and 72 h in media with and without com-
pounds. Both morphology and DNA fragmentation methods
assessed the percentage of neutrophil apoptosis in each culture.
The data obtained indicated that human neutrophils derived
from the peripheral blood of normal subjects undergo mor-
phological and chromatin fragmentation changes of pro-
grammed cell death (apoptosis). Upon measuring %
apoptosis of human neutrophils, the obtained results indicated
that the triazolopyrimidines 58 and 59 are the most active
members (Table 5). In addition, compounds 41 and 44 showed
promising activity. In case of compounds 41–45, the introduc-
tion of an electron donating group such as the OCH3 group at
the p-position of the phenyl ring favored the activity rather
than the electronegative moiety (Table 5). Moreover, com-
pounds 25–29 showed the lowest activity, this indicated that
these compounds exerted their activity through a mechanism
other than apoptosis; they possess higher afﬁnity toward
DNA and act through DNA binding.
4. Conclusion
New series of triazolopyrimidine and triazoloquinazoline ana-
logs of general formula (A–E) have been synthesized (Schemes
1–5). The newly synthesized compounds were evaluated for
their antitumor activity through screening their ability to inter-
act with the DNA which is known as the major mechanism of
action of several known antitumor agents. By observation of
the results of the in vitroDNA-binding test and the in vivo anti-
tumor testing against Ehrlich ascite carcinoma in mice for the
test compounds, the following items were observed: The mor-
pholine ring is essential for activity as most of the test com-
pounds containing this moiety proved to be active more than
those containing the N-methyl piperazine moiety. The phenyl
azo group proved to enhance in vitro activity especially when
attached to an electron-withdrawing group at the para posi-
tion. The diarylidene derivatives proved to be more active than
the mono derivatives and this appeared in the difference in
activity between compounds 44 and 49. The order of activity
has been changed in both in vitro and in vivo testing. This
inversion in activity order might be owed to pharmacokinetic
and pharmacodynamic considerations (such as; metabolism,
absorption, distribution, plasma-proteins binding, receptor site
interaction). This variation in results between the two testing
techniques might be considered also as an indication for the
inaccuracy of the DNA-binding as the only testing tool for
the evaluation of this class of antitumor compounds. For this
reason, the DNA-binding test was used in this investigation
only as a preliminary tool for the selection of the compoundsthat might show high activity in the in vivo testing. In addition,
the obtained data revealed that the triazolopyrimidinones
exhibited their antitumor activity through DNA binding.Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/
j.arabjc.2013.04.002.
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